MedTrace Logo

Glucagon Like Peptide 1 Receptor (GLP1R) Expression and Beta-cell Mass in Patients With Type 2 Diabetes

NCT04733508 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2021-02-02

No results posted yet for this study

Summary

Validation of the exendin-based beta cell imaging technique in patients with type 2 diabetes

Conditions

Interventions

DRUG

111In-DTPA-exendin-4

Injection of 111In-DTPA-exendin-4 and localization of the tracer in excised pancreatic tissue using autoradiography

DRUG

IRDye800CW-exendin-4

Injection of IRDye800CW-exendin-4 and localization of the tracer in excised pancreatic tissue using fluorescence microscopy

Sponsors & Collaborators

  • University of Coimbra

    collaborator OTHER

  • Radboud University Medical Center

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-01
Primary Completion
2022-06-01
Completion
2022-12-01

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04733508 on ClinicalTrials.gov